Goods & Services

pharmaceutical preparations for use in dermatology and oncology, for the treatment of infectious diseases, namely viral, bacterial, and fungal diseases, for treating pre-cancerous conditions of the eye and skin, and for treating inflammation medical devices for use in the treating or diagnosing of dermatological conditions or diseases, of cancer or pre-cancerous conditions, of infections, namely viral, bacterial, and fungal infections, of conditions of the eye and skin, and of inflammation distribution services, namely, delivery of pharmaceutical preparations and of medical devices custom manufacture of pharmaceuticals and of medical devices research and development in the fields of pharmaceutical products and of medical devices medical services

Goods & Services

product licensing, namely, licensing of pharmaceutical products and medical devices

Goods & Services

product licensing, namely, licensing of pharmaceutical products and medical devices

Goods & Services

pharmaceutical preparations for use in dermatology and oncology, for the treatment of infectious diseases, namely viral, bacterial, and fungal diseases, for treating pre-cancerous conditions of the eye and skin, and for treating inflammation medical devices for use in the treating or diagnosing of dermatological conditions or diseases, of cancer or pre-cancerous conditions, of infections namely viral, bacterial, and fungal, of conditions of the eye and skin, and of inflammation distribution services, namely, delivery of pharmaceutical preparations and of medical devices custom manufacture of pharmaceuticals research and development in the fields of pharmaceutical products and of medical devices medical services

Goods & Services

Nitric oxide releasing pharmaceutical preparations for use in dermatology and oncology and for the treatment of wounds and infectious disease

Abstract

Nitric oxide-releasing mesoporous silica nanoparticles (MSNs) were prepared using an aminosilane-template surfactant ion exchange reaction. Initially, bare silica particles were synthesized under basic conditions in the presence of cetyltrimethylammonium bromide (CTAB). These particles were functionalized with nitric oxide (NO) donor precursors via the addition of aminosilane directly to the particle sol, and a commensurate ion exchange reaction between the cationic aminosilanes and CTAB. N-diazeniumdiolate NO donors were formed at the secondary amines to yield NO-releasing silica MSNs. Tuning of the ion exchange-based MSN modification approach allowed for the preparation of monodisperse particles ranging from 30 to 1100 nm. Regardless of size, the MSNs stored appreciable levels of NO (0.4-1.5 μmol/mg) with tunable NO-release durations (1-33 h) dependent on the aminosilane modification. The range of MSN sizes and NO release demonstrate the versatility of this strategy.

IPC Classes  ?

• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C01B 21/24 - Nitric oxide (NO)
• C01B 33/18 - Preparation of finely divided silica neither in sol nor in gel formAfter-treatment thereof

Abstract

The present invention relates generally to suppositories that release nitric oxide, and methods of using the same.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Goods & Services

Pharmaceutical preparations for dermatological health; Pharmaceutical preparations for the skin and nails; Pharmaceutical preparations for treating acne; Pharmaceutical preparations for treating dermatosis; and Pharmaceutical preparations for treating dermatitis; Pharmaceutical preparations for treating herpes labialis; Pharmaceutical preparations for treating dermal ulcers; Pharmaceutical preparations for treating wounds; Pharmaceutical preparations for treating first and second degree burns; Pharmaceutical preparations for treating nail dystrophy

Abstract

Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.

IPC Classes  ?

• A61K 31/785 - Polymers containing nitrogen
• A61P 31/04 - Antibacterial agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Nitric oxide-releasing mesoporous silica nanoparticles (MSNs) were prepared using an aminosilane-template surfactant ion exchange reaction. Initially, bare silica particles were synthesized under basic conditions in the presence of cetyltrimethylammonium bromide (CTAB). These particles were functionalized with nitric oxide (NO) donor precursors via the addition of aminosilane directly to the particle sol, and a commensurate ion exchange reaction between the cationic aminosilanes and CTAB. N-diazeniumdiolate NO donors were formed at the secondary amines to yield NO-releasing silica MSNs. Tuning of the ion exchange-based MSN modification approach allowed for the preparation of monodisperse particles ranging from 30 to 1100 nm. Regardless of size, the MSNs stored appreciable levels of NO (0.4-1.5 μmol/mg) with tunable NO-release durations (1-33 h) dependent on the aminosilane modification. The range of MSN sizes and NO release demonstrate the versatility of this strategy.

IPC Classes  ?

• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C01B 21/24 - Nitric oxide (NO)
• C01B 33/18 - Preparation of finely divided silica neither in sol nor in gel formAfter-treatment thereof

Abstract

The presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides, in particular, polyglucosamines, and their use in biomedical and pharmaceutical applications. More particularly, in some embodiments, the presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides that release nitric oxide in a controlled and targeted manner, thereby prolonging the therapeutic effects of nitric oxide and improving the specificity of nitric oxide delivery to targeted cells and/or tissues.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• A61K 31/695 - Silicon compounds

Abstract

The presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides, in particular, polyglucosamines, and their use in biomedical and pharmaceutical applications. More particularly, in some embodiments, the presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides that release nitric oxide in a controlled and targeted manner, thereby prolonging the therapeutic effects of nitric oxide and improving the specificity of nitric oxide delivery to targeted cells and/or tissues.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/14 - Particulate form, e.g. powders
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• A61K 31/695 - Silicon compounds

Abstract

In one aspect, the subject matter disclosed herein is directed to NO-releasing functionalized nanorods having a desirable aspect ratio. The nanorods are also capable of releasing a desirable amount of NO (nitric oxide). In another aspect, the subject matter disclosed herein is directed to a composition comprising the NO-releasing nanorods. In another aspect, the subject matter disclosed herein is directed to methods of preparing NO-releasing nanorods having a specified aspect ratio. In another aspect, the subject matter disclosed herein is directed to a method of combating infection comprising administering to a subject a composition comprising NO-releasing nanorods, wherein the nanorods have a specified aspect ratio and NO-release profile.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• C07F 7/08 - Compounds having one or more C—Si linkages
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
• A61K 9/14 - Particulate form, e.g. powders
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• A61K 31/695 - Silicon compounds

Abstract

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 9/14 - Particulate form, e.g. powders

Goods & Services

Nitric oxide releasing pharmaceutical preparations for use in dermatology [ and oncology ] and for treatment of [ wounds and ] infectious disease

Goods & Services

Pharmaceutical preparations in the nature of compounds for the treatment of herpes